Sector News

Dispute brewing over exit of Protein Sciences CEO after Sanofi buyout

January 5, 2018
Life sciences

Not long after its acquisition by Sanofi, Protein Sciences is bidding adieu to its former leader. Yet Manon Cox says the departure wasn’t on her terms, according to the Meriden Record-Journal.

Cox will leave the company, a Sanofi spokesperson confirmed to FiercePharma. According to the Record-Journal, however, Cox claims she was forced out and has contacted an attorney. The publication also reported that Daniel Adams, former Protein Sciences head of business development, has been terminated. Adams cofounded Biogen in 1976, according to his profile on Protein Sciences’ website.

A Sanofi spokesperson said “Protein Sciences has been successfully and fully integrated into Sanofi Pasteur and, as such, there is no role of CEO for Protein Sciences. Sanofi Pasteur has acted in accordance with all obligations related to the Protein Sciences acquisition.”

Cox, who had been Protein Sciences’ CEO for 7 years, served as transition task force leader after the buyout, according to her LinkedIn profile. She served in managerial roles at Protein Sciences for nearly 20 years.

Sanofi picked up Protein Sciences last year after falling short in attempts to purchase Medivation and Actelion, bringing in an FDA-approved influenza vaccine that’s made with insect cells in an egg-free process. Sanofi Pasteur is the world’s No. 1 flu vaccine distributor and makes tens of millions of flu vaccine doses with eggs each year.

At the time, Sanofi Pasteur head David Loew said the purchase will allow the vaccines division of the global pharma giant to “broaden our flu portfolio with the addition of a non-egg based vaccine.” Cox praised Sanofi at the time of the buyout, saying she expected the company’s expertise in flu vaccines would help Flublok, its vaccine that hadn’t gained much traction in the market.

The outgoing CEO has long maintained Protein Sciences’ technology is superior to existing vaccines. When the Connecticut biotech won FDA approval for its FluBlok Quadrivalent back in 2016, Cox told FiercePharma she felt the company’s vaccine would be “the product of choice in time.”

“Even influenza vaccine manufacturers are recognizing that, over time, the egg-based production process will become obsolete and will be replaced with a more modern production process,” she said.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach